Lapatinib: A sword with two edges

Research output: Contribution to journalReview article

44 Citations (Scopus)


Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPathology and Oncology Research
Issue number1
Publication statusPublished - Mar 1 2008



  • Breast cancer
  • EGFR-inhibition
  • HER2-inhibition
  • Lapatinib
  • Targeted therapy
  • Trastuzumab resistency

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Oncology
  • Cancer Research

Cite this